Back to the search results

Universitätsklinikum Mannheim GmbH

Universitätsklinikum Mannheim GmbH
Universitätsklinikum Mannheim GmbH

Theodor-Kutzer-Ufer 1-3
68167 Mannheim

Phone: 0621-383-0
Fax: 0621-383-2185
Mail: ed.mmu@ofni

https://www.umm.de/start/
  • Number of beds: 1.352
  • Number of specialist departments: 27
  • Number of inpatient cases: 42.995
  • Number of partial inpatient cases: 4.407
  • Number of outpatient cases: 378.594
  • Hospital owners: Universitätsklinikum Mannheim GmbH
  • Type of provider: öffentlich
  • University Hospital
  • Academic teaching hospital
External comparative quality assurance
Further information
Bezeichnung
Teilnahme externe Qualitätssicherung yes
Bezeichnung
Teilnahme externe Qualitätssicherung yes
Bezeichnung
Teilnahme externe Qualitätssicherung yes
  • Quality of participation in the Disease Management Programme (DMP)
    No participation
Quantity performed 78
Exception? No exception
Quantity performed 25
Exception? No exception
Quantity performed 41
Exception? No exception
Quantity performed 57
Exception? No exception
Quantity performed 35
Exception? No exception
Quantity performed 58
Exception? No exception
Overall result forecast presentation: yes
Quantity performed reporting year: 78
Quantity forecast year: 74
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 25
Quantity forecast year: 32
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 57
Quantity forecast year: 49
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 35
Quantity forecast year: 49
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 58
Quantity forecast year: 71
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 0
Quantity forecast year: 19
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 41
Quantity forecast year: 44
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 0
Quantity forecast year: 188
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
No. Explanation
CQ30 Quality assurance guideline for interstitial LDR brachytherapy for low-risk localized prostate cancer (effective January 8, 2021).
CQ02 Quality assurance measures for the inpatient care of children and adolescents with haemato-oncological diseases
CQ24 Quality assurance measures for allogeneic stem cell transplantation for multiple myeloma (valid until 30 June 2022)
CQ03 Quality assurance measures for the implementation of positron emission tomography (PET) in hospitals for the indications non-small-cell lung cancer (NSCLC) and solid pulmonary nodules
CQ05 Measures for quality assurance in the care of pre-term and full-term neonates – Perinatal Centre LEVEL 1
CQ01 Quality assurance measures for inpatient care with the indication abdominal aortic aneurysm
  • Clarifying chat completed: no
  • Clarifying chat not completed: no
  • No participation in clarifying chat: no
  • Notification of non-fulfilment of nursing care not made: yes
Number Group
522 Medical specialists (m/f) , psychological psychotherapists (m/f) and child and adolescent psychotherapists (m/f) who are subject to the obligation to undergo further training*
380 Number of medical specialists (m/f) from no. 1 who have completed a five-year period of further training and are therefore subject to the obligation to provide evidence
380 Number of those persons from no. 2 who have provided proof of further training according to Article 3 of the G-BA regulations
* according to the “Provisions of the Joint Federal Committee for the Further Training of Medical Specialists (m/f), Psychological Psychotherapists (m/f) and Child and Adolescent Psychotherapists (m/f) in Hospitals”

According to Section 4 (2) of the Quality Management Guideline, facilities must provide for the prevention of and intervention in cases of violence and abuse as part of their internal quality management. The aim is to prevent, recognise and respond appropriately to abuse and violence, particularly against vulnerable patient groups such as children and adolescents or people in need of help, and also to prevent it within the facility. The respective procedure is aligned with the size of the facility, the range of services and the patients in order to define customised solutions for sensitising the teams as well as other suitable preventative and interventional measures. These may include information materials, contact addresses, training/education, codes of conduct, recommendations for action/intervention plans or comprehensive protection concepts.

Gemäß § 4 Absatz 2 in Verbindung mit Teil B Abschnitt I § 1 der Qualitätsmanagement-Richtlinie haben sich Einrichtungen, die Kinder und Jugendliche versorgen, gezielt mit der Prävention von und Intervention bei (sexueller) Gewalt und Missbrauch bei Kindern und Jugendlichen zu befassen (Risiko- und Gefährdungsanalyse) und – der Größe und Organisationsform der Einrichtung entsprechend – konkrete Schritte und Maßnahmen abzuleiten (Schutzkonzept). In diesem Abschnitt geben Krankenhäuser, die Kinder und Jugendliche versorgen, an, ob sie gemäß § 4 Absatz 2 in Verbindung mit Teil B Abschnitt I § 1 der Qualitätsmanagement-Richtlinie ein Schutzkonzept gegen (sexuelle) Gewalt bei Kindern und Jugendlichen aufweisen.
  • Drug commission

AMK_DA_Medikationsprozess AMK_DA_Dienstanweisung Arzneoimittel und Diagnostika

15.06.2021

  • Anwendung von gebrauchsfertigen Arzneimitteln bzw. Zubereitungen
  • Zentrale Herstellung von Zytostatikazubereitungen durch die Apotheke; Herstellung von Lösungen für die parenterale Ernährung (Neonatologie) durch die Apotheke; Herstellung von Schmerzmittelkassetten zur i.v. Applikation durch die Apotheke; Prozessanweisung "Vorbereitung und Applikation von i.v. Injektionen und Infusionen.
  • Vorhandensein von elektronischen Systemen zur Entscheidungsunterstützung (z.B. Meona®, Rpdoc®, AIDKlinik®, ID Medics® bzw. ID Diacos® Pharma)
  • Sonstige elektronische Unterstützung (bei z.B. Bestellung, Herstellung, Abgabe): Zenzy Programm für die Zentrale Zytostatikazubereitung
  • Teilnahme an einem einrichtungsübergreifenden Fehlermeldesystem (siehe Kapitel 12.2.3.2)
  • AMK_DA_Medikationsprozess
  • Aushändigung von arzneimittelbezogenen Informationen für die Weiterbehandlung und Anschlussversorgung der Patientin oder des Patienten im Rahmen eines (ggf. vorläufigen) Entlassbriefs
  • bei Bedarf Arzneimittel-Mitgabe oder Ausstellung von Entlassrezepten
The instruments and measures to promote drug therapy safety are presented with a focus on the typical procedures of the medication process in inpatient patient care. A special feature of the medication process in the inpatient environment is the transition management during admission and discharge. The instruments and measures listed below address structural elements, e.g. special IT equipment and work materials, as well as process aspects, such as work descriptions for particularly risky process steps or concepts for securing typical risk situations . In addition, proven measures to avoid or learn from medication errors can be specified. The hospital presents here which aspects it has already dealt with and which measures it has specifically implemented. The following aspects can be presented, if necessary using free text fields:
- Admission to hospital, including anamnesis
; Instruments and measures are presented for determining the old medication (drug history), the subsequent clinical assessment and the switch to the medication available in the hospital (house list), as well as for documenting both the patient's original medication and that for hospital treatment adapted medication.
- Medication process in the hospital
In this context, the following sub-processes are assumed as examples: drug history - prescription - patient information - drug delivery - drug use - documentation - therapy monitoring - result assessment. Instruments and measures for safe medication prescription can be presented, e.g. B. in terms of readability, clarity and completeness of the documentation, but also in terms of area of ​​application, effectiveness, benefit-risk ratio, tolerability (including potential contraindications, interactions, etc.) and resource considerations. Information can also be provided to support reliable medication ordering, delivery and use or administration.
- Discharge
In particular, the measures taken by hospitals can be presented to ensure that information on drug therapy is structured and passed on to doctors and physicians providing further treatment, as well as the appropriate provision of patients with drug information, medication plans and medications. Drug prescriptions are made.
AMTS is the totality of measures to ensure an optimal medication process with the aim of reducing medication errors and thus avoidable risks for patients during drug therapy. A prerequisite for the successful implementation of these measures is that AMTS is practised as an integral part of daily routine in an interdisciplinary and multi-professional approach.
Job
Explanation

Gemeinsame Doktorandenbetreuung mit ZI (Mannheim), Hochschule Mannheim, KIT (Karlsruhe), DKFZ (Heidelberg), Harvard University und anderen Fakultäten der Universität Heidelberg

Explanation

J. d. D. Dermatologischen Gesellschaft; Sportverletzung Sportschaden; Clin. a. Exp. Metastasis; Europ. J. of Pain; Int. J. of Cancer; Nature Scientific Rep.; Intraoperative Radiotherapy; Orthopädie und Unfallchirurgie; Atlas der MR-Angiographie.

Explanation

Gemeinsame Vorlesungen an der Universität Heidelberg zwischen Med. Fakultät Mannheim (MSc Biomedical Engineering ) und den Fakultäten Physik, Astronomie, Mathematik und Informatik.

Explanation

ACO/ARO/AIO 18.1, ENEST Freedom, BODO, DASFree, OPTIC, ENDURE, DAStop2, PONS, CLLRUmbrella1, Citadel-203

Explanation

GISG-06, CTCL, MINDED, NAUT, INTRABEAM, INTRAGO

Explanation

AIO-KRK-0214, PETRARCA, RAMSES, DANTE

Explanation

MWK-geförderte Studie zum Einfluss beruflich-praktischer Vorqualifikationen auf den Studienerfolg im Verbd. „Studierendenauswahl in der Medizin BW“; Aufbau Modellregion Ärztl. Ausbildung: Digitale Plattform zur Vernetzung mit Akad. LehrKH und Lehrpraxen BW, Teaching Cloud Medizin BW (TeaCM-BW).

Explanation

Lehre in den Studiengängen Medizintechnik und Medizinische Informatik an der Hochschule Mannheim.

Explanation

Akad. LehrKH: TKH MA, Diak. KH MA, Diak. SP, St. Marien KH LU, Klin. DA, Westpfalz-Klin. KL, KliLU, St. Josef KH HD, Hosp. R. Schumann LUX; Klin. Crailsheim; Akad. Lehrpraxen: PJ-Quartal "Amb. Med." u. "Allg.Med"; Famulatur: Med. Uni Ufa; Uni Potosí; Uni. del Rosario; Gulf Med. Uni. Dubai.

Training in other healing professions
Comment

Comment

Comment

Comment

Comment

Comment

Comment

Comment

Studium an der Hochschule für Wirtschaft und Gesellschaft Ludwigshafen und Praxis an der UMM.

Comment

Comment

Comment

Comment

Frau Hannelore Stendel-Kunter

Beschwerdemanager

Theodor-Kutzer-Ufer 1-3
68167 Mannheim

Phone: 0621 -383-3360
Mail: ed.mmu@tiehnedeirfuznetneitaP

Frau Larissa Goehner

Beschwerdemanager

Theodor-Kutzer-Ufer 1-3
68167 Mannheim

Phone: 0621 -383-3360
Mail: ed.mmu@tiehnedeirfuznetneitaP

Herr Christian Noll

Beschwerdemanager

Theodor-Kutzer-Ufer 1-3
68167 Mannheim

Phone: 0621 -383-3360
Mail: ed.mmu@tiehnedeirfuznetneitaP

Frau Magdalena Wolf-Seitz

Leitung

Theodor-Kutzer-Ufer 1-3
68167 Mannheim

Phone: 0621 -383-3456
Mail: ed.mmu@tnemeganamsteatilauQ

Herr Prof. Dr. med. Hans-Jürgen Hennes

Geschäftsführer und Ärztlicher Direktor

Theodor-Kutzer-Ufer 1-3
68167 Mannheim

Phone: 0621 -383-8900
Mail: ed.mmu@gnurheufstfeahcseG

Herr Dr. rer. nat. Andreas Danne

Leiter der Apotheke (Verantwortliche Person für Arzneimitteltherapiesicherheit)

Theodor-Kutzer-Ufer 1-3
68167 Mannheim

Phone: 0621 -383-2270
Mail: ed.mmu@ennaD.saerdnA

Frau Magdalena Wolf-Seitz

Leitung Stabsstelle Qualitätsmanagement

Theodor-Kutzer-Ufer 1-3
68167 Mannheim

Phone: 0621 -383-3456
Mail: ed.mmu@ztieS-floW.neladgaM

Herr Christian Noll

Beschwerdemanagement

Theodor-Kutzer-Ufer 1-3
68167 Mannheim

Phone: 0621 -383-3360
Mail: ed.mmu@tiehnedeirfuznetneitap

Theodor-Kutzer-Ufer 1-3
68167 Mannheim

Phone: 0621-383-0
Fax: 0621-383-2185
Mail: ed.mmu@ofni

Frau Yvonne Dintelmann

Pflegedirektorin seit 15.06.2019

Theodor-Kutzer-Ufer 1-3
68167 Mannheim

Phone: 0621 -383-2211
Mail: ed.mmu@nnamletniD.ennovY

Herr Freddy Bergmann

Kaufmännischer Geschäftsführer

Theodor-Kutzer-Ufer 1-3
68167 Mannheim

Phone: 0621 -383-5990
Mail: ed.mmu@gnurheufstfeahcseg

Herr Prof. Dr. med. Hans-Jürgen Hennes

Medizinischer Geschäftsführer und Ärztlicher Direktor

Theodor-Kutzer-Ufer 1-3
68167 Mannheim

Phone: 0621 -383-8900
Mail: ed.mmu@gnurheufstfeahcseG

Herr Prof. Dr. med. Hans-Jürgen Hennes

Medizinischer Geschäftsführer und Ärztlicher Direktor

Theodor-Kutzer-Ufer 1-3
68167 Mannheim

Phone: 0621 -383-8900
Mail: ed.mmu@gnurheufstfeahcseG

No

IK: 260820569

Location number: 772389000

Old location number: 772389000

Hospital portrait for download